Eosinophil Peroxidase–Associated PRKCB–CCL4/CCR5 Signaling in Chronic Rhinosinusitis with Nasal Polyps
This study demonstrates that eosinophil peroxidase (EPX) drives chronic rhinosinusitis with nasal polyps-associated epithelial inflammation by activating the PRKCB–CCL4/CCR5 signaling pathway, suggesting this axis as a potential therapeutic target.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The nose is more than a gateway for air; it is a complex landscape of delicate tissue that must constantly balance defense against invaders with the need to breathe freely. In a condition known as chronic rhinosinusitis with nasal polyps, this balance collapses. The lining of the nose becomes swollen and inflamed, growing into soft, grape-like clumps that block the sinuses. For many patients, this is driven by a specific type of immune response where white blood cells called eosinophils gather in large numbers. These cells are part of the body's defense system, but when they become overactive, they release a flood of chemical signals and toxic proteins that damage the tissue and keep the inflammation going. While doctors know that these cells are present, the exact chain of events that turns their activity into a self-sustaining cycle of disease has remained a mystery. Understanding this chain is crucial because current treatments often fail to stop the polyps from returning, leaving patients with persistent breathing problems and a reduced quality of life.
A team of researchers set out to map this hidden chain of events by looking directly at the proteins inside the nasal tissue of patients. They gathered samples from sixty-nine individuals with the condition and compared them to samples from thirty-nine people with healthy noses. Using a high-powered method that can identify and count thousands of proteins at once, they scanned the tissue to see which molecules were behaving differently. The analysis revealed a massive shift in the chemical environment of the diseased nose, with nearly two thousand proteins showing altered levels. Among this sea of changes, one protein stood out as being present in vastly higher amounts in the patients: eosinophil peroxidase. This is a toxic enzyme released by eosinophils, and its abundance suggested it might be a key driver of the problem rather than just a bystander.
To confirm this suspicion, the scientists examined the tissue more closely and found that the levels of this enzyme were indeed much higher in the polyps than in healthy tissue. They then moved to a living model to test what would happen if they stopped this enzyme from working. They created a version of the disease in mice and used a specialized virus to silence the gene responsible for making eosinophil peroxidase. When the mice were treated with this virus, the damage to their nasal lining improved significantly. The swelling went down, the number of invading immune cells decreased, and the levels of other inflammatory chemicals dropped. This experiment provided strong evidence that removing this single protein could calm the entire inflammatory storm, suggesting that the enzyme plays a central role in keeping the disease alive.
The researchers then wanted to know how a protein released by a white blood cell could cause such widespread changes in the nose. They traced the path of the signal and found that the enzyme appears to trigger a specific chain reaction within the cells that line the nasal passages. When the enzyme is present, it activates a molecular switch inside these cells, which then turns on a set of genes that recruit more immune cells to the area. Specifically, the enzyme seemed to activate a pathway involving a protein called PRKCB, which in turn boosted the production of two other molecules, CCL4 and CCR5. These molecules act like sirens, calling more inflammatory cells to the site and worsening the swelling.
To prove this connection, the team tested human nasal cells in a dish. They added the enzyme to the cells and watched as the levels of the PRKCB, CCL4, and CCR5 molecules rose. Then, they added a chemical blocker that stops the PRKCB switch from working. When this blocker was present, the enzyme could no longer trigger the rise in the other molecules. This showed that the enzyme relies on this specific switch to send its damaging signals. The study did not claim to have found a cure, but it did identify a clear, step-by-step mechanism: the enzyme released by eosinophils activates a specific pathway in nasal cells that recruits more inflammation. By pinpointing this exact route, the researchers have provided a new target for future therapies that could potentially break the cycle of disease and offer relief to those who do not respond to current treatments.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.